5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

+ [1]

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [6]

Active Indication

Depressive Disorder, MajorDepressive Disorder, Treatment-ResistantStimulant abuse+ [37]

Inactive Indication

Major depressive disorder, moderate (MDD)Mild depressionModerate depression+ [1]

Originator Organization-

Active Organization

Apex Labs Ltd.Startup

MYND Life Sciences, Inc.

Usona Institute

+ [26]

Inactive Organization

Cybin, Inc.

Beckley Psytech Ltd.Startup

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (EU), Breakthrough Therapy (US), Innovative Licensing and Access Pathway (GB)

Structure

Molecular FormulaC12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS Registry520-52-5

226

Clinical Trials associated with Psilocybin

NCT06005662 / SuspendedPhase 2IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Start Date01 Apr 2027

Sponsor / Collaborator

The Johns Hopkins University

ACTRN12624000816550 / Not yet recruitingPhase 2

Feasibility Study of the Effect of Psilocybin in Response to Brief Psychological Input with Psychological Flexibility as a Mediating Factor on adults with Mild to Moderate Depression or Anxiety.

Start Date01 May 2025

Sponsor / Collaborator

University of Otago

NCT06367738 / Not yet recruitingPhase 1IIT

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

The investigators will use cognitive exams, perceptual tasks, brain imaging, peripheral psychophysiology, and surveys to investigate the persisting effects of psilocybin on cognition, predictive coding, and affect in healthy older adults. The investigators will measure changes in these measures by comparing baseline to one-week and one-month post-treatment. Participants will be randomly assigned to receive a dose of psilocybin in a range from microdose to moderate-to-high dose. Dose response will be assessed. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity. The investigators will assess whether changes in these brain measures underlie observed changes in cognition, predictive coding and affect.

Start Date01 Apr 2025

Sponsor / Collaborator

University of California, Berkeley

100 Clinical Results associated with Psilocybin

100 Translational Medicine associated with Psilocybin

100 Patents (Medical) associated with Psilocybin

1,836

Literatures (Medical) associated with Psilocybin

01 Feb 2025·Journal of Affective Disorders

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study

Article

Author: Carhart-Harris, Robin ; Sepeda, Nathan ; Kettner, Hannes ; Jackson, Heather ; Jones, Grant ; Lowe, Matthew X ; Lowe, Matthew X. ; Nayak, Sandeep ; Garcia-Romeu, Albert

BACKGROUNDPsilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture as a number of clinical and observational studies have demonstrated that it may have potential for improving mental wellbeing. Relatedly, there has been a substantial uptick in naturalistic (e.g., real-world, non-clinical) psilocybin use in the United States. While a number of longitudinal studies have demonstrated that naturalistic psilocybin use is linked to positive mental health outcomes on average, few studies have examined how the effects of psilocybin and contexts for psilocybin use may differ for White populations compared to Populations of Color.OBJECTIVETo examine differences in health outcomes, subjective effects, and contexts of naturalistic psilocybin use in White participants compared to Participants of Color.METHODSThis study used data from a large, online longitudinal study of individuals who planned to engage in naturalistic psilocybin use (N = 2833). We used mixed-effects models to assess whether race/ethnicity (White vs. Participant of Color) moderated associations between time (Time 2 [initial assessment point for longitudinal measures], Time 5 [2-4 weeks post-psilocybin experience, and Time 6 [2-3 months post-experience]) and outcomes related to mental health (depression, anxiety, spiritual wellbeing, cognitive flexibility, emotion regulation [expressive suppression + cognitive reappraisal]). We also used exploratory chi-squared tests to examine differences in contexts for psilocybin use as well as differences in subjective effects related to the psilocybin experience.RESULTSRace/ethnicity moderated the associations between time for predicting spiritual wellbeing (beta = -1.8; 95 % CI [-3.4, -0.17]; p < 0.05), cognitive flexibility (beta = -1.5 [-2.7, -0.26]; p < 0.05), and emotion regulation - expressive suppression (beta = 0.25 [0.06, 0.44]; p < 0.05) at Time 6 (but not Time 5). Additionally, Participants of Color reported minor differences in subjective effects and context for use compared to White participants (e.g., more likely to have set an intention prior to use, report time speeding up during the experience, etc.). We found reductions in anxiety and depression for both Participants of Color and White participants, and our moderation tests for these outcomes were not significant.CONCLUSIONRace/ethnicity impacts the associations between psilocybin use and various markers of mental wellbeing. Future longitudinal studies and experimental studies with larger samples of color can further elucidate the preliminary findings from this study.

01 Jan 2025·Journal of Affective Disorders

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis

Review

Author: Liang, Chih-Sung ; Yu, Chia-Ling ; Kao, Yu-Chen ; Hsu, Tien-Wei ; Yang, Fu-Chi ; Li, Jia-Ru ; Chiang, Kuo-Tung

Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide [LSD], 3,4-Methylenedioxymethamphetamine [MDMA], and ayahuasca) in adult patients with depressive symptoms. We only considered oral psychedelic-assisted therapy without concomitant use of antidepressants. The primary outcome was the change in depressive symptoms. There were five study designs of psychedelic trials, including non-active-drug-as-placebo, active-drug-as-placebo, waitlist-as-control, fixed-order, and pre-post designs. In non-active-drug -as-placebo design, psilocybin (k = 4, Hedges' g [g] = 0.87, 95 % confidence intervals[CIs] = 0.58 to 1.16) and MDMA (k = 2, g = 0.65, 95%CIs = 0.26 to 1.05) were associated with large and medium effect sizes, respectively. In active-drug-as-placebo design, both psilocybin (k = 2, g = 0.71, 95%CIs = -0.01 to 1.43) and MDMA (k = 3, g = 0.53, 95%CIs = -0.23 to 1.28) were not statistically significant. In pre-post single-arm (k = 3, g = 2.51, 95%CIs = 1.00 to 4.02) and waitlist-as-control (k = 1, g = 2.88, 95%CIs = 1.75 to 4.00) designs, psilocybin showed a large effect size of antidepressant effect. Ayahuasca also showed a large effect size in both pre-post (k = 2, g = 1.88, 95%CIs = 1.18 to 2.57) and non-active-drug-as-placebo (k = 1, g = 1.60, 95%CIs = 0.84 to 2.36) designs. LSD was associated with a significant antidepressant effect only in non-active-drug-as-placebo design (k = 1, g = 1.49, 95%CIs = 0.80 to 2.17) but not in active-drug-as-placebo design (k = 1, g = 0.44, 95%CIs = -0.90 to 1.78). The antidepressant effects of psychedelics may be overestimated in studies with pre-post single-arm, non-active-drugs-as placebo, and waitlist-control designs. Restricted sample size, difficulty with establishing blinding for participants, and over expectancy limit the estimation of the antidepressant effect of psychedelic-assisted therapy.

01 Jan 2025·European Journal of Medicinal Chemistry

Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT2A receptor activation and psychedelic-like activity

Article

Author: Wang, Xiaohui ; Wang, Yibo ; Yang, Yuefeng ; Sun, Jinpeng ; Wang, Hongshuang ; Xiao, Peng ; Wen, Xin ; Yang, Zhishuai ; Zhang, Cong ; Zhang, Miyuan

Recent advancements in the study of mushroom-derived tryptamines, particularly psilocybin and its metabolite psilocin, highlight their unique psychedelic properties and potential therapeutic applications, especially for mental health conditions like depression. This study examines how the position of the hydroxyl group on the indole ring affects the 5-HT_2A receptor activity and psychedelic-like effects of psilocin analogs. Chemically synthesized psilocin (1) and its analogs bufotenine (2), 6-OH-DMT (3), and 7-OH-DMT (4) were assessed for 5-HT_2A receptor agonistic activity using the Gα_q-Gγ dissociation bioluminescence resonance energy transfer (BRET) assay and for psychedelic-like effects through the head-twitch response assay. Results show that compounds with hydroxyl group at the 4th and 5th positions exhibit significantly higher 5-HT_2A agonistic and psychedelic-like activities than those with hydroxyl group at the 6th and 7th positions. Funnel metadynamics simulations revealed that psilocin (1) and bufotenine (2) have lower binding free energies, correlating with experimental data. Analysis of the simulation trajectories reveals that the formation of a hydrogen bond with residue L229 is crucial for guiding psilocin (1) and bufotenine (2) into the 5-HT_2AR binding site. In contrast, analogs 3 and 4, which lack this interaction, fail to be directed into the orthosteric site. Furthermore, psilocin (1) and bufotenine (2) establish a stable salt bridge and hydrogen bond with residue D155. These interactions are more stable compared to those formed by ligands 3 and 4, contributing to the latter's poor 5-HT_2AR activities. These findings underscore the critical role of the hydroxyl group position on the indole ring in modulating 5-HT_2A receptor activity and the corresponding psychedelic-like effects, offering valuable insights for the development of targeted therapeutics.

858

News (Medical) associated with Psilocybin

18 Nov 2024

·endpts.com

Cybin says its psychedelic drug can sustain remission in depression patients

Cybin said its psilocin analog has the potential to wipe out symptoms in most patients with a serious form of depression, which marks a major step over just using antidepressants. In a small Phase 2 trial in major depressive disorder, two doses of 16 mg CYB003 led to a 100% response rate in the Montgomery–Åsberg Depression Rating Scale (MADRS) at 12 months, with 71% of patients in remission. The results demonstrate “consistent, robust and sustained” benefits after the company previously reported 75% of patients were in remission at four months, chief medical officer Amir Inamdar said in a Monday release. The standard of care for MDD is selective serotonin reuptake inhibitors (SSRIs), but only a third of patients find themselves in remission after six weeks of daily dosing, CEO Doug Drysdale told Endpoints News in an interview. Another setback of SSRIs is that patients can experience a reduction in positive and negative emotions, which can feel as though they’re in “chemical handcuffs,” he added. In the Phase 2 trial, patients took CYB003 on top of their standard medication so they didn’t have to go through the “challenging process” of titrating off of their background medications, Drysdale said. But the idea is that once patients have a response with CYB003, they could come off these background drugs, he said. And so, instead of taking an SSRI tablet every day for years, the patient can just take two doses of CYB003 over a 12-month period, he added. Cybin’s Phase 2 study was designed to evaluate two oral doses of CYB003 — 12 mg or 16 mg — taken twice three weeks apart. Eight patients completed 12 months of follow-up with the 16 mg dose, with seven of them getting two doses and the eighth getting a single dose. CYB003 was well tolerated in the study with no serious adverse events and zero reports of suicidality or suicidal ideation. The most common side effects were nausea, headache and transient elevated blood pressure, but these occurred only during the dosing sessions, Drysdale said. Last week, the Canadian biotech kicked off its Phase 3 program for CYB003, which comprises three trials. One trial will have three arms testing two doses of 16 mg treatment, two doses of 8 mg and two doses of placebo. “The goal there is to cancel out expectancy bias,” Drysdale said. In October, Compass Pathways delayed highly-anticipated Phase 3 readouts for its psilocybin asset, COMP360, in treatment-resistant depression. In contrast to Compass’ drug, CYB003 is based on psilocin, which is the “active part” of psilocybin, Drysdale said. “We’ve removed that metabolic step and the deuteration appears to improve the pharmacokinetics,” he added.

Phase 2Phase 3Clinical Result

18 Nov 2024

·firstwordpharma.com

Can Cybin break the psychedelic glass ceiling?

Calling results from a handful of patients who received synthetic psilocybin analogue CYB003 for major depressive disorder (MDD) "remarkable," Cybin's chief executive projected confidence in the asset on Monday, just days after launching a three-study Phase III programme. But whether the company can overcome the psychedelic pitfalls that have plagued other drug developers this year remains to be seen, especially as investors had a less than enthusiastic response to the data readout, sending Cybin's shares down 10% in Toronto and nearly 9% in New York on Monday.The company touted a 12-month 100% response rate for the seven patients who received two 16-mg doses of CYB003 three weeks apart. Of those patients, five (71%) achieved MDD remission at the one-year mark, as defined by a Montgomery-Asberg Depression Rating Scale (MADRS) total score ≤10.The average baseline MADRS score, including both the 16-mg and 12-mg dosing groups, was 32. Those who received the high-dose regimen saw a mean MADRS reduction of 23 points at 12 months. "Up to two thirds of MDD patients do not achieve remission with first-line antidepressants, which have defined the current treatment standard. With CYB003, we have the opportunity to pivot away from the chronic, daily treatments that often only offer symptomatic relief, and move towards more patient-friendly infrequent, long-lasting therapeutics for MDD patients who do not achieve remission with existing treatments," said CEO Doug Drysdale. "CYB003’s two doses per treatment cycle have the potential to free up capacity for new patients and improve accessibility to treatment." The candidate received breakthrough therapy designation from the FDA in March.Psychedelic setbacksWith the FDA rejection of Lykos Therapeutics' MDMA-based therapeutic in August, mood disorder experts are now looking ahead to late-stage psilocybin treatments as the most likely candidates to crack the psychedelic glass ceiling (see – KOL Views Q&A: Psychedelic developers need to learn from Lykos but all eyes now on make-or-break psilocybin efforts, says leading psychiatrist).FirstWord recently spoke with Collin Reiff, an assistant professor of psychiatry at New York University Grossman School of Medicine, who noted that Compass Pathways' clinical strategy for its synthetic psilocybin therapy COMP360 in treatment-resistant depression "is very smart. They are going about this in a very methodical way that should give them a good chance at success." However, Compass had its own setback last month when it announced that the pivotal readout for COMP360 — originally expected by year-end — has been pushed back to the second quarter of 2025. The data delay was also accompanied by a workforce reduction affecting 30% of Compass' employees (see – Spotlight On: Another confidence-shaker in psychedelic space arrives via Compass).The decision looks to have been an attempt by Compass to avoid one of the biggest issues that the FDA had with Lykos' data package for MDMA-assisted therapy — that its clinical trials were "functionally unblinded" since most patients guessed they had received the experimental treatment.Concerns over unblinding may have also spilled over into Cybin's stock move on Monday. While the firm was upbeat about the results of its Phase II trial and its newly launched Phase III PARADIGM programme, the available details on the three planned pivotal studies' design don't address how Cybin plans to ensure the integrity of its data.

Phase 3Clinical ResultPhase 2Breakthrough Therapy

14 Nov 2024

·www.globenewswire.com

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiation of dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. “Dosing of the first subjects in the Phase 1 study is an important milestone for REL-P11, a low-dose, modified-release psilocybin formulation. Preclinical rodent studies, published at the American Association for the Study of Liver Disease in 2023 (AASLD 2023), showed that treatment with REL-P11 improved multiple metabolic parameters with no detrimental CNS effects, and suggest that REL-P11 could have potential to become a valuable therapeutic option in the evolving obesity and metabolic syndrome space,” said Sergio Traversa, Chief Executive Officer of Relmada. “We expect the Phase 1 study to help define the pharmacokinetic, safety and tolerability profile of REL-P11 and, with positive data, pave the way for a Phase 2a proof-of-concept study to begin in H1 2025.” About REL-P11 and the Phase 1 StudyRelmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. Relmada identified the potential to use low-dose psilocybin as a treatment for metabolic diseases and published the data at the American Society for the Study of Liver Disease (AASLD 2023). About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com. Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects”, "anticipates”, "believes”, "will”, "will likely result”, "will continue”, "plans to”, "potential”, "promising”, and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the Reliance-OLS (study 310) to accurately reflect the results of the ongoing Reliance II (study 302) and Relight (study 304) blinded, randomized and controlled studies of REL-1017, failure of the ongoing Phase 1 and planned Phase 2a trials of REL-P11, the Company’s low-dose, modified release formulation of psilocybin, to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. Investor Contact:Tim McCarthyLifeSci AdvisorsTim@LifeSciAdvisors.com Media Inquiries:Corporate Communicationsmedia@relmada.com

Phase 2Phase 1AACR

100 Deals associated with Psilocybin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Psilocybin	-	DB11664

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Treatment-Resistant	Phase 3	US	Compass Pathways Plc	19 Jan 2023
Depressive Disorder, Major	Phase 3	DE	ATAI Life Sciences NV	-
Bipolar II disorder	Phase 2	US	Compass Pathways Plc	01 Mar 2021
Body Dysmorphic Disorders	Phase 2	US	Compass Pathways Plc	26 Feb 2021
Cocaine-Related Disorders	Phase 2	US	The University of Alabama at Birmingham	01 May 2015
Alcoholism	Phase 2	-	-	-
Generalized anxiety disorder	Phase 2	-	Incannex Healthcare, Inc.	-
Headache	Phase 2	-	-	-
Major depressive disorder, moderate (MDD)	Phase 1	US	Usona Institute	15 Oct 2019
Major depressive disorder, moderate (MDD)	Preclinical	US	Usona Institute	15 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Placebo (Psilocybin)	ljfssjjruk(duvqlpajvk) = bdsnnazimx hkqjatagml (rxucforlqc, qunareddfc - oolmrmmymy) View more	-	24 Oct 2024
NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Escitalopram (Escitalopram)	ljfssjjruk(duvqlpajvk) = xfgvbdwtsn hkqjatagml (rxucforlqc, wdngmwyqux - rmjekxshny) View more	-	24 Oct 2024
NCT03429075 (Literature) Manual	Phase 2	Major depressive disorder, moderate (MDD)	59	Psilocybin combined with psychological support	(lqynfsnuws): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311 View more	Positive	21 Sep 2024
NCT03429075 (Literature) Manual	Phase 2	Major depressive disorder, moderate (MDD)	59	Escitalopram combined with psychological support		Positive	21 Sep 2024
NCT04661514 (Pubmed)	Phase 1	Anorexia Nervosa	10	Psilocybin	jofurvslbm(iugttmosjb) = Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. umpdmjaukb (urumlhqlkh )	Positive	01 Jul 2024
NCT05312151 (GlobeNewswire) Manual	Phase 2	Stress Disorders, Post-Traumatic	22	COMP360 psilocybin	(wqskdnsyqx) = There were no treatment-emergent serious adverse events. ldjhumanvw (yaorbuiecd ) Met View more	Positive	08 May 2024
Psi-GAD1 (NEWS) Manual	Phase 2	Generalized anxiety disorder	72	Psilocybin	(hbjbwcipxs) = wtghvjfdnu wsemftuqwv (ypwqkpcpmo ) Met	Positive	28 Feb 2024
Psi-GAD1 (NEWS) Manual	Phase 2	Generalized anxiety disorder	72	Psilocybin	(hbjbwcipxs) = glfmptuktt wsemftuqwv (ypwqkpcpmo ) Met	Positive	28 Feb 2024
NCT04593563 (Literature) Manual	Phase 2	Depressive Disorder, Major Adjuvant	30	Psilocybin	(cpdjsuxyba) = ugryuxbkga dgxfniofca (ytiqpftmhj, 22.3 to -16.0)	Positive	18 Dec 2023
GlobeNewswire Manual	Phase 2	Bipolar II disorder	15	psilocybin 25mg	(neazwaiypz) = ynilkqubyl rnvqytjggk (uylyycsvam ) View more	Positive	06 Dec 2023
NCT04739865 (CTgov)	Phase 2	Depressive Disorder, Treatment-Resistant	19	Psilocybin	jbbiewhhih(zaqbzvprac) = gxrdvfrbxe mvcbtnmkhw (sqciwjjqtr, nkfxluqmsn - icdlqbtitt) View more	-	09 Nov 2023
NCT01534494 (CTgov)	Phase 2	Alcoholism	10	Psilocybin	yvypnsmfig(wuklzwujim) = ggcowjazhi mzvqjbzkqv (ikekyrdxpd, bumlcvqwvl - kvwwvihgkx) View more	-	26 Sep 2023
ASCO2023	Not Applicable	Neoplasms \| Depressive Disorder, Major	30	Psilocybin-assisted group therapy	(ugjhriykgl) = dmzkrsagsi rfwdegonrm (ltpnpgnnhv ) View more	Positive	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis